Mersana Therapeutics, Inc. (MRSN)
Largest Insider Buys in Sector
MRSN Stock Price History Chart
MRSN Stock Performance
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana …
Insider Activity of Mersana Therapeutics, Inc.
Over the last 12 months, insiders at Mersana Therapeutics, Inc. have bought $0 and sold $394,264 worth of Mersana Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Mersana Therapeutics, Inc. have bought $33M and sold $1.19M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,760 shares for transaction amount of $47,182 was made by Hack Andrew A. F. () on 2022‑05‑31.
List of Insider Buy and Sell Transactions, Mersana Therapeutics, Inc.
| 2024-10-28 | Sale | SVP, Chief Development Officer | 1,884 0.0014% | $1.90 | $3,580 | +2.11% | ||
| 2024-10-03 | Sale | SVP, Chief Sci.&Tech. Officer | 5,598 0.0048% | $1.96 | $10,972 | +3.96% | ||
| 2024-10-03 | Sale | SVP, COO & CFO | 5,598 0.0048% | $1.96 | $10,972 | +3.96% | ||
| 2024-10-03 | Sale | SVP, Chief Legal Officer | 5,598 0.0048% | $1.96 | $10,972 | +3.96% | ||
| 2024-10-03 | Sale | SVP, Chief Development Officer | 5,598 0.0048% | $1.96 | $10,972 | +3.96% | ||
| 2024-10-03 | Sale | VP, Chief Accounting Officer | 3,361 0.0029% | $1.96 | $6,588 | +3.96% | ||
| 2024-10-02 | Sale | SVP, Chief Sci.&Tech. Officer | 8,089 0.0071% | $2.00 | $16,178 | +2.94% | ||
| 2024-10-02 | Sale | SVP, COO & CFO | 8,089 0.0071% | $2.00 | $16,178 | +2.94% | ||
| 2024-10-02 | Sale | SVP, Chief Legal Officer | 8,089 0.0071% | $2.00 | $16,178 | +2.94% | ||
| 2024-10-02 | Sale | SVP, Chief Development Officer | 8,089 0.0071% | $2.00 | $16,178 | +2.94% | ||
| 2024-10-02 | Sale | VP, Chief Accounting Officer | 4,855 0.0043% | $2.00 | $9,710 | +2.94% | ||
| 2024-09-12 | Sale | President, CEO | 50,423 0.0409% | $1.76 | $88,744 | +16.38% | ||
| 2024-01-16 | Sale | SVP, Chief Sci.&Tech. Officer | 10,409 0.0086% | $2.71 | $28,208 | -6.27% | ||
| 2024-01-16 | Sale | director | 29,399 0.0243% | $2.71 | $79,671 | -6.27% | ||
| 2024-01-16 | Sale | SVP, COO & CFO | 9,327 0.0077% | $2.71 | $25,276 | -6.27% | ||
| 2024-01-16 | Sale | SVP, Chief Legal Officer | 4,381 0.0036% | $2.71 | $11,873 | -6.27% | ||
| 2024-01-16 | Sale | VP, Chief Accounting Officer | 5,025 0.0042% | $2.71 | $13,618 | -6.27% | ||
| 2024-01-16 | Sale | SVP, Chief Manuf. Officer | 3,357 0.0028% | $2.71 | $9,097 | -6.27% | ||
| 2024-01-16 | Sale | SVP, Chief Development Officer | 3,431 0.0028% | $2.71 | $9,298 | -6.27% | ||
| 2023-10-26 | Sale | SVP, Chief Development Officer | 1,912 0.0014% | $1.13 | $2,161 | +85.95% |
Insider Historical Profitability
| Mandelia Ashish | VP, Chief Accounting Officer | 47757 0.0387% | $1.97 | 1 | 9 | <0.0001% |
| New Enterprise Associates 14, L.P. | 10 percent owner | 11959520 9.6812% | $1.97 | 2 | 1 | +8.86% |
| Hack Andrew A. F. | 8663673 7.0132% | $1.97 | 17 | 0 | +48.09% | |
| BARRIS PETER J | 10 percent owner | 8140138 6.5894% | $1.97 | 1 | 0 | +20.77% |
| BARRETT M JAMES | 10 percent owner | 8140138 6.5894% | $1.97 | 1 | 0 | +20.77% |
Institutional Investor Ownership
| Ecor1 Capital Llc | $86.75M | 15.83 | 19.36M | 0% | +$0 | 0.61 | |
| Vr Adviser Llc | $50.75M | 9.26 | 11.33M | 0% | +$0 | 2.47 | |
| Bain Capital Life Sciences Investors Llc | $38.81M | 7.08 | 8.66M | 0% | +$0 | 3.12 | |
| BlackRock | $36.27M | 6.62 | 8.1M | +3.21% | +$1.13M | <0.01 | |
| The Vanguard Group | $28.11M | 5.13 | 6.27M | +0.59% | +$164,783.36 | <0.01 |